How Beta Sheets Form and Why Mutations Disrupt Them
Beta sheets are secondary structures in proteins where polypeptide chains align side-by-side via hydrogen bonds, creating stable, pleated sheets essential for protein folding and function. Mutations—often amino acid substitutions—can alter this by changing side chain properties, disrupting hydrogen bonding, or introducing steric clashes, leading to misfolded proteins.[1][2]
Effects on Protein Stability and Aggregation
Mutations in beta sheet regions frequently destabilize the structure, reducing thermal stability and promoting aggregation. For instance, in amyloid diseases like Alzheimer's, beta sheet mutations in amyloid-beta or tau proteins enhance fibril formation, forming toxic plaques that impair neuronal function.[3] Similarly, in prion diseases, mutations expand beta sheets in PrP, converting alpha-helices to beta-sheets and triggering self-propagating aggregates that cause neurodegeneration.[4]
Impact on Enzymes and Signaling Proteins
In enzymes, beta sheet mutations can distort active sites. Mutations in beta sheets of superoxide dismutase (SOD1) in ALS patients reduce dimer stability, leading to toxic gain-of-function via aggregates that damage motor neurons.[5] Signaling proteins like p53 see beta sheet mutations (e.g., at residues 171-181) that unfold the DNA-binding domain, halting tumor suppression and promoting cancer.[6]
Consequences for Cellular Processes
- Proteostasis Overload: Misfolded proteins from beta sheet mutations activate the unfolded protein response (UPR), causing ER stress, autophagy overload, and apoptosis if unresolved.[2][7]
- Membrane and Trafficking Issues: Mutations can impair beta sheet-mediated membrane insertion, as in cystic fibrosis (CFTR DeltaF508 mutation near beta sheets), blocking chloride channel trafficking and causing ion imbalance.[8]
- Immune and Inflammatory Responses: In immunoglobulins, beta sheet mutations weaken antigen binding, impairing immune recognition; in inflammatory contexts, they exacerbate cytokine storms via aggregate-induced inflammation.[9]
Disease Examples and Mechanisms
| Disease | Protein | Mutation Effect | Cellular Impact |
|---------|---------|-----------------|---------------|
| Alzheimer's | Amyloid-beta | Expands beta sheets | Synaptic loss, neuronal death [3] |
| ALS | SOD1 | Destabilizes beta barrel | Mitochondrial dysfunction, axonopathy [5] |
| Huntington's | Huntingtin | Polyglutamine inserts disrupt sheets | Transcriptional dysregulation [10] |
| Type II Diabetes | Islet amyloid polypeptide (IAPP) | Beta sheet fibrillization | Beta-cell apoptosis [11] |
These mutations often lead to dominant-negative effects or toxic aggregates cleared inefficiently by cells, amplifying dysfunction.
Therapeutic Approaches Targeting Beta Sheet Mutations
Small molecules like stabilizers (e.g., vatiquinone for SOD1) or antibodies (e.g., aducanumab for amyloid) aim to prevent misfolding. Gene therapies editing beta sheet regions show promise in models, but off-target risks remain.[12][13]
What Predicts Severity of Beta Sheet Mutations?
Hydrophobic core mutations cause more aggregation than surface ones; computational tools like FoldX predict impacts by scoring DeltaG changes.[1][14]
[1] Nature Reviews Molecular Cell Biology - Protein Folding and Misfolding
[2] Cell - Beta-Sheet Structures in Disease
[3] Neuron - Amyloid-beta Beta Sheets
[4] Science - Prion Beta Sheet Conversion
[5] Nature Neuroscience - SOD1 Mutations
[6] Cancer Research - p53 Beta Sheet Mutations
[7] Annual Review of Biochemistry - UPR in Misfolding
[8] Journal of Clinical Investigation - CFTR Folding
[9] Immunity - Antibody Beta Sheets
[10] Nature Reviews Neuroscience - Huntingtin Pathology
[11] Diabetes - IAPP Amyloids
[12] Nature Medicine - ALS Therapies
[13] New England Journal of Medicine - Aducanumab
[14] Bioinformatics - FoldX Tool